HIV persistence in tissues on dolutegravir-based therapy is not associated with resistance mutations to dolutegravir

Communications Medicine 2026 Open access

Read full text
Authors: Gilbert Mchantaf, Adeline Melard, Kévin Da Silva, Elise Gardiennet, Antoine Chaillon, Bénédicte Lefebvre, Jade Ghosn, Olivier Robineau, Jean-Paul Viard, Lucie Adoux, Frédéric Lemoine, Aurélie Barrail-Tran
+5 more Sylvie Orr, Fatoumata Coulibaly, Laurence Meyer, Antoine Cheret, Véronique Avettand-Fenoel
DOI: 10.1038/s43856-026-01405-z
Cited by: 3
References: 46

Abstract

Relatively few studies have investigated HIV-1 persistence in tissues, especially in healthy people-living-with-HIV-1 (PLWH) on a successful antiretroviral regimen containing second generation integrase inhibitors. In the ANRS EP64 DOLUVOIR, we explore HIV-1 persistence in five accessible anatomical sites in 20 PLWH on an efficient first-line ART regimen containing dolutegravir with virological load

Fields of Study & Subjects

HIV/AIDS drug development and treatment HIV Research and Treatment HIV-related health complications and treatments

Publication details

Journal / source
Communications Medicine
Publisher
Springer Science and Business Media LLC
Volume
6
Issue
1
Publication date
27 January 2026
Language
EN